-
Antiviral API
- Arenavirus
- Cytomegalovirus (CMV)
- Dengue virus
- Endogenous Metabolite
- Enterovirus (EV)
- Epstein-Barr virus (EBV)
- Filovirus
- Flavivirus
- HCV Protease
- Hepatitis B Virus (HBV)
- Hepatitis C Virus (HCV)
- Herpes simplex Virus (HSV)
- HIF/HIF Prolyl-Hydroxylase
- HIV Integrase
- HIV Protease
- Human immunodeficiency Virus (HIV)
- Human papillomavirus (HPV)
- Influenza Virus
- Nipah virus
- Orthopoxvirus
- Others
- Rabies virus (RABV)
- Respiratory syncytial Virus (RSV)
- Reverse Transcriptases (RTs)
- SARS-CoV
- Tobacco mosaic virus (TMV)
- Vesicular stomatitis virus (VSV)
- Virus Protease
- West Nile virus
- Antiviral intermediates
Oltipraz
![{PARAM:[Name]}()](https://resource.bocsci.com/structure/64224-21-1.gif)
| Category | Human immunodeficiency Virus (HIV) |
| CAS | 64224-21-1 |
| Description | Oltipraz, a promising cancer chemopreventive agent, is a bifunctional inducer, modulating both phase I and II drug-metabolizing enzymes to enhance carcinogen detoxification. |
Product Information
| Synonyms | CD1400; CD 1400; CD-1400 |
| IUPAC Name | 4-methyl-5-pyrazin-2-yldithiole-3-thione |
| Molecular Weight | 226.33 |
| Molecular Formula | C8H6N2S3 |
| Canonical SMILES | CC1=C(SSC1=S)C2=NC=CN=C2 |
| InChI | InChI=1S/C8H6N2S3/c1-5-7(12-13-8(5)11)6-4-9-2-3-10-6/h2-4H,1H3 |
| InChIKey | CKNAQFVBEHDJQV-UHFFFAOYSA-N |
| Boiling Point | 408.1±55.0 °C at 760 mmHg |
| Melting Point | 165-166°C |
| Flash Point | 200.6±31.5 °C |
| Purity | >98% |
| Density | 1.5±0.1 g/cm3 |
| Solubility | In vitro: 10 mM in DMSO |
| Appearance | Dark red solid |
| Application | Anticarcinogenic Agents |
| Storage | Powder: -20°C: 3 years 4°C: 2 years In solvent: -80°C: 6 months -20°C: 1 month |
| Complexity | 262 |
| Exact Mass | 225.96931172 |
| Index Of Refraction | 1.760 |
| In Vitro | Oltipraz inhibits HIF-1α activity and HIF-1α-dependent tumor growth, which may result from a decrease in HIF-1α stability through S6K1 inhibition in combination with an H2O2-scavenging effect. Oltipraz treatment also inhibits HIF-1α activation stimulated by either hypoxia or CoCl2. Oltipraz is a cancer chemopreventive agent and has an inhibitory effect on angiogenesis and tumor growth. Oltipraz is also a competitive inhibitor of this cytochrome P450, with an apparent Ki of 10 μM. |
| In Vivo | In wild-type mice, hepatic levels of mRNA for all of the genes analyzed were significantly increased after Oltipraz treatment, with the highest increase (treated/control) for NQO1 mRNA levels (7.6-fold). The Northern blot analyses demonstrated that the observed increases in GST and NQO1 activities by Oltipraz in wild-type mice were preceded by significant elevations in RNA expression. Interestingly, mRNA levels of Nrf2 itself were increased more than 3-fold by Oltipraz treatment. |
| PSA | 114.35000 |
| Target | HIF/HIF Prolyl-Hydroxylase; HIV; Keap1-Nrf2 |
| Vapor Pressure | 0.0±0.9 mmHg at 25°C |
| XLogP3-AA | 1.1 |
